Compared to monotherapy combination of pills for advanced skin cancer extends survival

November 23, 2015

The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.3 months)

Previous Article
Leading University of Leicester experts to discuss climate issues at Framing the Climate Crisis event
Leading University of Leicester experts to discuss climate issues at Framing the Climate Crisis event

Leading experts from the University of Leicester will be discussing prominent environmental issues - includ...

Next Article
Vibration-based therapy can successfully treat apnea events in preterm infants
Vibration-based therapy can successfully treat apnea events in preterm infants

Researchers from Beth Israel Deaconess Medical Center's Neonatal Intensive Care Unit (NICU), the Wyss Insti...